AURA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.25 USD | +3.13% |
|
+4.32% | -18.17% |
Presenter SpeechTazeen Ahmad (Analysts)Joining us on this webcast. I am Tazeen Ahmad. I'm one ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.25
USD
Average target price
19.8
USD
Spread / Average Target
+173.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.17% | 348M | |
| +54.05% | 63.85B | |
| -2.02% | 41.83B | |
| +40.01% | 40.47B | |
| -10.22% | 27.17B | |
| +13.42% | 26.52B | |
| -21.60% | 18.69B | |
| +2.89% | 12.73B | |
| +22.40% | 12.11B | |
| +27.49% | 12.07B |
- Stock Market
- Equities
- AURA Stock
- News Aura Biosciences, Inc.
- Transcript : Aura Biosciences, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 04
